PEGylated liposomes are generally thought to reduce immunogenicity of the vesicles and prolong the circulation time in vivo, and have been widely recognized as one of the most successful strategies to improve the delivery of therapeutic molecules. However, PEGylated-liposomes have recently been demonstrated to show side effects. For example, PEGylated liposomal doxorubicin presents palmar plantar erythrodysesthesia while the Non-PEGylated formula does not. Our non-PEGylated liposome (NPL) technology has been established to provide an alternative carrier with lower toxicity allowing for a higher accumulative dose.
This promotion has ended.
The winner will be announced soon.